Northern Ireland Executive
13 Jan 2022, 17:30 GMT+10
Health Minister Robin Swann has confirmed that Kaftrio will be made available to suitable patients aged six years and older in Northern Ireland for the treatment of cystic fibrosis (CF).
Kaftrio was initially approved for use in Northern Ireland in 2020 following an agreement with its supplier Vertex Pharmaceuticals which gave access to people with CF over the age of 12 in line with a European-wide license. The recent extension means that clinically suitable children aged six and over can now benefit from Kaftrio.
The Minister said: "This decision will mean a great deal to the children with cystic fibrosis who are suitable for this treatment in Northern Ireland. This licence extension is included as part of the deal agreed with the supplier, Vertex in 2020. I am very pleased that this cutting-edge medicine will be available to more of our cystic fibrosis patient population and allow them to have a better quality of life."
The move applies to patients who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and follows a recommendation by the European Medicines Agency (EMA).
Providing and delivering Kaftrio to patients is a complex process. This triple combination treatment (Kaftrio) combines three drugs which perform different functions - ivacaftor, tezacaftor and elexacaftor. Therefore a number of different healthcare professionals will work together to ensure patients are managed properly.
The Minister went on to say:
"When a new treatment becomes available it is fully understandable that patients and families should want immediate access to it. However, not all patients aged six to 11 with cystic fibrosis will be suitable for treatment with Kaftrio, and not everyone can be seen immediately by the multi-disciplinary teams who need to make this determination. The Health Service is working hard to make this treatment available to those who can benefit as soon as possible and I would therefore ask you to continue to be patient and let the clinical teams prioritise those patients who are in most need to be seen first."
Get a daily dose of Irish Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Irish Sun.
More InformationMOSCOW, Russia: Just hours after his sudden dismissal by President Vladimir Putin, Russia's former transport minister, Roman Starovoit,...
DHARAMSHALA, India: The Dalai Lama turned 90 on July 6, celebrated by thousands of followers in the Himalayan town of Dharamshala,...
ZAGREB, Croatia: A massive concert by popular Croatian singer Marko Perković, known by his stage name Thompson, has drawn widespread...
WASHINGTON, D.C.: Elon Musk's entry into the political arena is drawing pushback from top U.S. officials and investors, as his decision...
CULVER CITY, California: TikTok is preparing to roll out a separate version of its app for U.S. users, as efforts to secure a sale...
WASHINGTON, D.C.: President Donald Trump claimed he was unaware that the term shylock is regarded as antisemitic when he used it in...
ZAGREB, Croatia: A massive concert by popular Croatian singer Marko Perković, known by his stage name Thompson, has drawn widespread...
DUBLIN, Ireland: Despite extreme heat gripping much of mainland Europe, Irish holidaymakers are pressing ahead with their travel plans,...
HONG KONG: China has fired back at the European Union in an escalating trade dispute by imposing new restrictions on medical device...
PARIS, France: A strike by French air traffic controllers demanding improved working conditions caused significant disruptions during...
ROME, Italy: Quick thinking by emergency responders helped prevent greater devastation after a gas station explosion in southeastern...
WASHINGTON, D.C.: President Donald Trump is drawing praise from his core supporters after halting key arms shipments to Ukraine, a...